"Ovary-sparing hysterectomy raises the risk for accelerated menopause, according to a study published online April 4 in Obstetrics Gynecology.
Removing the ovaries at the time of hysterectomy in women at low risk for ovarian ca"...
Jinteli™ (norethindrone acetate and ethinyl estradiol tablets, USP) are indicated in women with an intact uterus for the:
- Treatment of moderate to severe vasomotor symptoms associated with the menopause.
- Prevention of postmenopausal osteoporosis. When
prescribing solely for the prevention of postmenopausal osteoporosis, therapy
should only be considered for women at significant risk of osteoporosis.
Non-estrogen medications should be carefully considered.
The mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women.
Risk factors for osteoporosis include low bone mineral density, low estrogen levels, family history of osteoporosis, previous fracture, small frame (low BMI), light skin color, smoking, and alcohol intake. Response to therapy can be predicted by pre-treatment serum estradiol, and can be assessed during treatment by measuring biochemical markers of bone formation/resorption, and/or bone mineral density.
Estrogen therapy reduces bone resorption and retards or halts postmenopausal bone loss. Studies have shown a risk ratio of about 0.4 for hip and wrist fractures in women whose estrogen therapy was begun within a few years of menopause, compared to women taking calcium and vitamin D alone. Studies also suggest that estrogen reduces the rate of vertebral fractures. Even when started as late as 6 years after menopause, estrogen reduces further loss of bone mass for as long as treatment is continued. When estrogen therapy is discontinued, bone mass declines at a rate comparable to the immediate postmenopausal period.
Data from the Women's Health Initiative study showed that use of estrogen plus progestin (dose equivalent to 0.625 CE and 2.5 mg MPA) resulted in about 5 less hip fractures per 10,000 womenyears, compared to use of placebo (risk ratio about 0.66).
DOSAGE AND ADMINISTRATION
Use of estrogen, alone or in combination with a progestin, should be limited to the shortest duration consistent with treatment goals and risks for individual woman. Patients should be reevaluated periodically as clinically appropriate (e.g., 3 to 6 month intervals) to determine if treatment is still necessary (See BOXED WARNING and WARNINGS.) For women who have a uterus, adequate diagnostic measures, such as endometrial sampling, when indicated, should be undertaken to rule out malignancy in cases of undiagnosed persistent or recurring abnormal vaginal bleeding. Patients should be evaluated for breast abnormalities in accordance with good clinical practice. Patients should be started at the lowest dose. Jinteli therapy consists of a single tablet taken once daily.
For the Treatment Of Moderate To Severe Vasomotor Symptoms Associated With The Menopause
Jinteli tablets should be given once daily for the treatment of moderate to severe vasomotor symptoms associated with the menopause. Patients should be reevaluated at 3 to 6 month intervals to determine if treatment is still necessary.
For Prevention of Postmenopausal Osteoporosis
When prescribing solely of the prevention of postmenopausal osteoporosis, Jinteli tablets should only be prescribed to postmenopausal women who are at significant risk of osteoporosis. Non-estrogen medications should be carefully considered. Risk factors for osteoporosis include low bone mineral density, low estrogen levels, family history of osteoporosis, previous fracture, small frame (low BMI), light skin color, smoking, and alcohol intake. Patients should be treated with the lowest effective dose. This dose should be periodically reassessed by the healthcare provider. Response to therapy can be assessed during treatment by measuring biochemical markers of bone formation/resorption, and/or bone mineral density.
Jinteli™ (norethindrone acetate and ethinyl estradiol tablets, USP) are available as:
|1 mg/5 mcg:||White, round, flat-faced, beveled-edge, unscored tablet. Debossed with stylized b on one side and 125 on the other side. Available in:|
|Bottle of 90 Tablets||NDC 00933122-98|
|5 Blister Cards of 28 Tablets per Carton||NDC 00933122-42|
KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.
Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].
Manufactured By: Barr Laboratories, Inc. Pomona, NY 10970. Manufactured For: Teva Pharmaceuticals USA Sellersville, PA 18960. Issued November 2009This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 3/31/2014
Additional Jinteli Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.